Logo

American Heart Association

  8
  0


Final ID:

Discussant: FLOW

  • Rangaswami, Janani  ( Washington DC VA Medical Center , Washington DC , District of Columbia , United States )
  • Deboer, Ian  ( Washington DC VA Medical Center , Washington DC , District of Columbia , United States )
  • Vaduganathan, Muthiah  ( Brigham and Womens Hospital , Boston , Massachusetts , United States )
  • Author Disclosures:
    Janani Rangaswami: DO have relevant financial relationships ; Consultant:Boehringer Ingelheim:Active (exists now) ; Consultant:Bioporto:Active (exists now) ; Consultant:Bayer:Active (exists now) ; Consultant:procyrion:Active (exists now) | IAN DEBOER: No Answer | Muthiah Vaduganathan: DO have relevant financial relationships ; Researcher:received research grant support, served on advisory boards, or had speaker engagements with American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, BMS, Boehringer Ingelheim, Chiesi, Cytokinetics, Lexicon Pharmaceuticals, Merck, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health, and participates on clinical trial committees for studies sponsored by AstraZeneca, Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Incretin Modulation: Is a New Standard of Care Emerging?

Monday, 11/18/2024 , 01:30PM - 02:45PM

Featured Science

More abstracts on this topic:
Discussant: SUMMIT CMR

Kramer Chris, Rider Oliver, Wilcox Jane

Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Cardiovascular Status or Risk in the FLOW trial

Tuttle Katherine, Mann Johannes, Perkovic Vlado, Pratley Richard, Ridker Paul, Rossing Peter, Schmieder Roland, Shamkhalova Minara S., Sreenivasamurthy L, Mahaffey Kenneth, Bakris George, Bang Casper, Bax Willem, Belmar Nicolas, Brown Paul, Cherney David, Chernin Gil, Lim Soo Kun

You have to be authorized to contact abstract author. Please, Login
Not Available